Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021000584 - THROMBIN BINDING CIRCULAR APTAMER AND USE THEREOF

Publication Number WO/2021/000584
Publication Date 07.01.2021
International Application No. PCT/CN2020/073684
International Filing Date 22.01.2020
IPC
C12N 15/115 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
A61K 31/7088 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
A61P 1/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
A61P 9/14 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
A61P 13/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
Applicants
  • 合肥工业大学 HEFEI UNIVERSITY OF TECHNOLOGY [CN]/[CN]
Inventors
  • 郑磊 ZHENG, Lei
  • 毛瑜 MAO, Yu
Agents
  • 北京思创大成知识产权代理有限公司 BEIJING SICHUANG DACHENG INTELLECTUAL PROPERTY AGENCY CO., LTD.
Priority Data
201910595164.603.07.2019CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) THROMBIN BINDING CIRCULAR APTAMER AND USE THEREOF
(FR) APTAMÈRE CIRCULAIRE SE LIANT À LA THROMBINE ET UTILISATION ASSOCIÉE
(ZH) 凝血酶环状核酸适配体及其应用
Abstract
(EN)
Provided is a thrombin binding circular aptamer, and the nucleotide sequence thereof is selected from at least one of a)-d): a) a nucleotide sequence as shown in SEQ ID NO:1, wherein the 5' end and 3' end are connected into a ring; b) a nucleotide sequence obtained from the nucleotide sequence as shown in SEQ ID NO:1 through substitution, said obtained nucleotide sequence having circular DNA molecules capable of specifically recognizing thrombin; c) a nucleotide sequence obtained from the nucleotide sequence as shown in SEQ ID NO:1 through deficiency, said obtained nucleotide sequence having circular DNA molecules capable of specifically recognize thrombin; d) a nucleotide sequence obtained from the nucleotide sequence as shown in SEQ ID NO:1 by adding one or more nucleotides, said obtained nucleotide sequence having circular DNA molecules capable of specifically recognize thrombin; and e) a nucleotide sequence obtained from the nucleotide sequence as shown in SEQ ID NO:1 through modification with a chemical group. The thrombin binding circular aptamer specifically recognizes thrombin, and the half-life thereof is up to 8 hours.
(FR)
L'invention concerne un aptamère circulaire se liant à la thrombine et sa séquence nucléotidique est choisie parmi au moins un élément parmi les éléments a) à d) : a) une séquence nucléotidique telle que représentée dans la SEQ ID NO : 1, l'extrémité 5' et l'extrémité 3' étant reliées pour former un cycle; b) une séquence nucléotidique obtenue à partir de la séquence nucléotidique telle que représentée dans la SEQ ID NO : 1 par substitution, ladite séquence nucléotidique obtenue comprenant des molécules d'ADN circulaires capables de reconnaître spécifiquement la thrombine; c) une séquence nucléotidique obtenue à partir de la séquence nucléotidique telle que représentée dans la SEQ ID NO : 1 par délétion, ladite séquence nucléotidique obtenue comprenant des molécules d'ADN circulaires capables de reconnaître spécifiquement la thrombine; d) une séquence nucléotidique obtenue à partir de la séquence nucléotidique telle que représentée dans la SEQ ID NO : 1 en ajoutant un ou plusieurs nucléotides, ladite séquence nucléotidique obtenue comprenant des molécules d'ADN circulaires capables de reconnaître spécifiquement la thrombine; et e) une séquence nucléotidique obtenue à partir de la séquence nucléotidique telle que représentée dans la SEQ ID NO : 1 par modification avec un groupe chimique. L'aptamère circulaire se liant à la thrombine reconnaît spécifiquement la thrombine et sa demi-vie est jusqu'à 8 heures.
(ZH)
提供了一种凝血酶环状核酸适配体,其核苷酸序列选自a)~d)中至少一种:a)SEQ ID NO:1所示的核苷酸序列且5'端和3'端连接成环;b)SEQ ID NO:1所示的核苷酸序列经取代获得的核苷酸序列,并且具有特异性识别凝血酶功能的环状DNA分子;c)SEQ ID NO:1所示的核苷酸序列经缺失获得的核苷酸序列,并且具有特异性识别凝血酶功能的环状DNA分子;d)SEQ ID NO:1所示的核苷酸序列经添加一个或多个核苷酸获得的核苷酸序列,并且具有特异性识别凝血酶功能的环状DNA分子;e)SEQ ID NO:1所示的核苷酸序列经化学基团修饰的核苷酸序列。所述凝血酶核酸适配体特异性识别凝血酶,半衰期可达8小时。
Latest bibliographic data on file with the International Bureau